- Home
- BEAM vs MIRM Comparison
BEAM vs MIRM Comparison
Compare BEAM & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- MIRM
- Stock Information
- Founded
- BEAM 2017
- MIRM 2018
- Country
- BEAM United States
- MIRM United States
- Employees
- BEAM N/A
- MIRM N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- BEAM Health Care
- MIRM Health Care
- Exchange
- BEAM Nasdaq
- MIRM Nasdaq
- Market Cap
- BEAM 1.9B
- MIRM 2.1B
- IPO Year
- BEAM 2020
- MIRM 2019
- Fundamental
- Price
- BEAM $24.41
- MIRM $47.98
- Analyst Decision
- BEAM Buy
- MIRM Strong Buy
- Analyst Count
- BEAM 10
- MIRM 11
- Target Price
- BEAM $47.67
- MIRM $57.00
- AVG Volume (30 Days)
- BEAM 1.2M
- MIRM 432.9K
- Earning Date
- BEAM 02-25-2025
- MIRM 02-26-2025
- Dividend Yield
- BEAM N/A
- MIRM N/A
- EPS Growth
- BEAM N/A
- MIRM N/A
- EPS
- BEAM N/A
- MIRM N/A
- Revenue
- BEAM $349,643,000.00
- MIRM $307,028,000.00
- Revenue This Year
- BEAM N/A
- MIRM $82.63
- Revenue Next Year
- BEAM $14.08
- MIRM $26.43
- P/E Ratio
- BEAM N/A
- MIRM N/A
- Revenue Growth
- BEAM 328.73
- MIRM 112.14
- 52 Week Low
- BEAM $20.84
- MIRM $23.14
- 52 Week High
- BEAM $49.50
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- BEAM 42.12
- MIRM 68.78
- Support Level
- BEAM $22.50
- MIRM $45.26
- Resistance Level
- BEAM $28.39
- MIRM $47.25
- Average True Range (ATR)
- BEAM 1.56
- MIRM 1.56
- MACD
- BEAM -0.33
- MIRM 0.66
- Stochastic Oscillator
- BEAM 27.67
- MIRM 91.60
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.